Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level.
| INTRODUCTION
The direct oral anticoagulants (DOACs) comprise the direct thrombin inhibitor, dabigatran, and the direct factor Xa inhibitors, apixaban, betrixaban, edoxaban, and rivaroxaban. Collectively, these agents have been approved by the United States Food and Drug Administration (US FDA) for prevention of stroke and systemic embolism in non-valvular atrial fibrillation, prevention and treatment of venous thromboembolism (VTE), and secondary prevention of arterial ischemic events in patients with chronic coronary or peripheral artery disease.
1-5 As a class, DOACs have now eclipsed vitamin K antagonists (VKAs) as the most widely prescribed oral anticoagulants in the Unites States and elsewhere. [6] [7] [8] Adam Cuker and Allison Burnett are co-first authors.
Two key advantages of the DOACs compared with VKAs are a reduced incidence of major bleeding and simplified perioperative management. 9, 10 Nevertheless, patients taking DOACs may present with serious bleeding or need for an urgent unplanned procedure. Major bleeding was reported in 2.1% to 3.6% of patients randomized to treatment with a DOAC in phase III clinical trials. Two DOACs, along with warfarin, are among the top ten drugs contributing to emergency department visits in the US. 9, 11, 12 Two specific DOAC reversal agents have been approved by the US The purpose of this document is to provide clinical guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding the use of DOAC reversal agents based upon the best available information, including situations in which high-quality evidence is absent. We discuss indications for DOAC reversal, provide detailed guidance on how the individual reversal agents should be administered, and offer suggestions for management strategies and stewardship at the health system level.
| METHODS
As with previous Anticoagulation Forum guidance documents, 17 we prioritized a set of key questions regarding DOAC reversal through discussion and consensus among the authors (Table 1) . We searched PubMed to identify evidence related to these questions. This search was supplemented by articles from the authors' files and manual review of references. We prioritized studies of patients that reported patient-important outcomes (ie, bleeding, thromboembolism, mortality) over in vitro, animal, and healthy volunteer studies. We also reviewed relevant information in US FDA product package inserts and on www.clinicaltrials.gov.
For each question, a summary of the evidence is provided, followed by guidance representing unanimous consensus of the authors.
3 | GUIDANCE 3.1 | (1) When should reversal agents be used to manage DOAC-associated bleeding?
| Evidence summary
Even before specific reversal agents for the DOACs became available, outcomes of DOAC-associated bleeding compared favorably with VKAs. In a 2015 meta-analysis of 13 randomized trials involving more than 100 000 patients, DOACs were associated with a 47% reduction in the risk of fatal bleeding (RR 0.53, 95% CI 0.43-0.64) compared with VKAs. 18 
| Guidance statement 1
In all patients with DOAC-associated major bleeding, we suggest treatment with supportive measures. We suggest administration of a reversal agent only if bleeding is life-threatening, into a critical organ, or is not controlled with maximal supportive measures and there is demonstration or reasonable expectation that the patient has clinically relevant plasma DOAC levels.
3.2 | (2) How should reversal agents be used to manage dabigatran-associated bleeding?
| Evidence summary
Idarucizumab, a humanized, monoclonal, anti-dabigatran antibody fragment, was evaluated in 301 patients with dabigatran-associated major bleeding in the REVERSE-AD study. 21 The most common sites of bleeding were gastrointestinal and intracranial. Of 203 evaluable patients, 134 (68%) had cessation of bleeding within 24 h. The median time to achievement of hemostasis was 2.5 h. The relationship between reduction in plasma dabigatran levels and hemostatic efficacy was not reported. Approximately one quarter of patients experienced a re-elevation in plasma dabigatran levels 24 h after idarucizumab infusion. Treatment was generally well-tolerated. The thrombotic rate in the overall study cohort was 4.8% at 1 month.
Events included VTE (n = 10), ischemic stroke (n = 7), myocardial infarction (n = 6), and systemic embolism (n = 2). Half of thrombotic events occurred within 5 days of infusion and one-third occurred after resumption of anticoagulation. Anti-idarucizumab antibodies were present in 3.8% of subjects at study entry; an additional 1.9% developed antibodies after infusion. Titers were low and did not appear to interfere with idarucizumab activity. 21 Idarucizumab was approved by the US FDA in 2015 for dabigatran reversal. 13 The dose is 5 g (two 2.5 g vials). The label allows for re-dosing if coagulation parameters become re-elevated and clinically relevant bleeding occurs.
APCC is a plasma-derived concentrate of the vitamin K-dependent clotting factors in which a fraction of the clotting factors has been activated by proteolytic cleavage. APCC was evaluated in 14 patients with dabigatran-associated major bleeding. In all patients with DOAC-associated major bleeding, we suggest treatment with supportive measures. We suggest administration of a reversal agent only if bleeding is life-threatening, into a critical organ, or is not controlled with maximal supportive measures and there is demonstration or reasonable expectation that the patient has clinically relevant plasma DOAC levels.
(2) How should reversal agents be used to manage dabigatranassociated bleeding?
In patients with dabigatran-associated major bleeding in whom a reversal agent is warranted, we suggest treatment with idarucizumab 5 g IV. If idarucizumab is not available, we suggest treatment with APCC 50 units/kg IV.
(3) How should reversal agents be used to manage factor Xa inhibitor-associated bleeding?
In patients with rivaroxaban-associated or apixaban-associated major bleeding in whom a reversal agent is warranted, we suggest treatment with andexanet alfa dosed according to the US FDA label (Table 2) . If andexanet alfa is not available, we suggest treatment with four-factor PCC 2000 units. In patients with edoxaban-associated or betrixaban-associated major bleeding in whom a reversal agent is warranted, we suggest off-label treatment with either high dose andexanet alfa (800 mg bolus given at 30 mg/min followed by a continuous infusion of 8 mg/min for up to 120 min) or four-factor PCC 2000 units.
(4) When should reversal agents be used before an invasive procedure?
In DOAC-treated patients who require an invasive procedure, we suggest that a reversal agent be administered only if the procedure cannot be safely performed while the patient is anticoagulated, cannot be delayed, and there is demonstration or reasonable expectation that the patient has clinically relevant plasma DOAC levels.
(5) How should reversal agents be used to manage a dabigatrantreated patient before an invasive procedure?
In dabigatran-treated patients who require an urgent procedure and in whom a reversal agent is warranted, we suggest treatment with idarucizumab 5 g IV. If idarucizumab is not available, we suggest treatment with APCC 50 units/kg IV.
(6) How should reversal agents be used to manage a factor Xa inhibitor-treated patient before an invasive procedure?
In factor Xa inhibitor-treated patients who require an urgent procedure and in whom a reversal agent is warranted, we suggest treatment with andexanet alfa at the same dosing used for major bleeding. If andexanet alfa is not available, we suggest treatment with four-factor PCC 2000 units. In patients with DOAC overdose without bleeding, we suggest against the routine use of reversal agents. In DOAC-treated patients who present with trauma without bleeding, we suggest against the routine use of reversal agents.
(9) What strategies can be employed by health systems to promote optimal utilization of DOAC reversal agents?
To promote optimal use of DOAC reversal, we suggest that health systems develop and implement overarching strategies that promote multidisciplinary, shared stewardship of these agents. We suggest utilization of evidence-based clinical tools and processes that facilitate adherence with agreed-upon restrictions for judicious prescribing and use. We suggest system-level approaches be streamlined to the fullest extent possible via leveraging of the electronic health record, as well as maximized efficiency of pharmacy order processing, admixture, and delivery strategies. We further suggest that health systems develop contingency plans to be prepared for a variety of acquisition challenges, as well as close collaboration with vendors and billing departments to capitalize on cost mitigation opportunities. We suggest periodic formal evaluation of DOAC reversal practices to assess for appropriateness and identify opportunities for further optimization. Lastly, we suggest that dedicated stewardship programs be established, whenever possible, to drive development, implementation, consistent application, and evaluation of anticoagulation-related optimization strategies including, but not limited to, appropriate and judicious use of DOAC reversal agents.
Abbreviations: APCC, activated prothrombin complex concentrate; DOAC, direct oral anticoagulant; PCC, prothrombin complex concentrate; US FDA, United States Food and Drug Administration.
1 to 14 h after the first dose. Hemostasis was adjudicated as good in 9 (64%), moderate in 5 (36%), and poor in none. There were no thromboembolic events. 22 PCC and recombinant factor VIIa for dabigatran reversal have been investigated in in vitro, animal, and healthy volunteer studies (reviewed in 23 ), but not in prospective studies of patients with dabigatran-associated bleeding.
Hemodialysis may be used to remove dabigatran from the circulation. 24 In patients with renal impairment, a single session typically reduces plasma drug levels by about 50%. 25 In practice, it is often impractical to place a dialysis catheter and initiate hemodialysis in a coagulopathic patient with serious bleeding due to the bleeding risk and time-consuming nature of the procedure.
| Guidance statement 2
In patients with dabigatran-associated major bleeding in whom a reversal agent is warranted (see guidance statement 1), we suggest treatment with idarucizumab 5 g IV. If idarucizumab is not available, we suggest treatment with APCC 50 units/kg IV.
| (3)
How should reversal agents be used to manage factor Xa inhibitor-associated bleeding?
| Evidence summary
Andexanet alfa is a modified recombinant factor Xa. It is catalytically inactive and cannot participate in coagulation, but it retains the ability to bind to and sequester factor Xa inhibitors. It was approved by the US FDA in May 2018 for management of life-threatening or uncontrollable bleeding in patients taking apixaban or rivaroxaban based on the "Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors" (ANNEXA-4) study.
26
The ANNEXA-4 study enrolled 352 patients (128 on rivaroxaban, 194 on apixaban, 10 on edoxaban, and 20 on enoxaparin). The two most common primary sites of bleeding were intracranial (64%) and gastrointestinal (26%). A low dose of andexanet alfa (400 mg bolus given over 15 to 30 min followed by a continuous infusion of 4 mg/min for 120 min) was administered to patients on apixaban and those who had last taken rivaroxaban >7 h ago. A high dose (800 mg bolus given over 30 min followed by a continuous infusion of 8 mg/min for 120 min) was administered to patients who had taken rivaroxaban within the last 7 h, or at an unknown time, as well as those who had received edoxaban or enoxaparin. 26 An efficacy analysis was conducted in 134 patients on apixaban and 100 patients on rivaroxaban, who met criteria for major bleeding and had a plasma DOAC level ≥75 ng/mL at study entry. The mean reduction in anti-Xa activity at the completion of the andexanet alfa bolus was 92%. Hemostasis was judged to be good or excellent in 83% and 80% of apixaban-treated and rivaroxaban-treated patients,
respectively. There was no significant relationship between reduction in anti-Xa activity and hemostatic efficacy. 26 A safety analysis was undertaken in the overall study population.
Forty thrombotic events (7 myocardial infarctions, 15 transient ischemic attacks or ischemic strokes, 18 VTEs) occurred in 34 (10%) patients at 30 days. Eleven patients had a thromboembolic event within 5 days of receiving andexanet alfa and 8 patients had an event after restarting anticoagulation. 26 The US FDA prescribing information for andexanet alfa includes a black box warning regarding the risk of venous and arterial thromboembolic events. 14 Dosing instructions from the prescribing information 14 are summarized in Table 2 , and differ slightly from the dosing used in ANNEXA-4. Andexanet alfa has been shown to reverse edoxaban in a rabbit bleeding model and in healthy volunteers. 27, 28 Only 10 edoxabantreated patients were enrolled in ANNEXA-4, though there is a plan to enroll more in an extension of the study in Germany and Japan. 26 Andexanet alfa also reversed betrixaban in a healthy control study. 29, 30 There are no published outcomes of andexanet alfa in betrixaban-treated patients.
PCCs are plasma-derived concentrates of the vitamin K-dependent clotting factors in their inactive form. Four-factor PCC contains factors II, VII, IX, and X, whereas three-factor PCC contains predominantly factors II, IX, and X, and no or trivial concentrations of factor VII. PCC for reversal of bleeding in patients taking factor Xa inhibitors has been evaluated in two prospective cohort studies. In a Swedish study, 84 patients with factor Xa inhibitor-associated major bleeding were treated with four-factor PCC. Patients weighing <65 kg received 1500 units; patients weighing >65 kg received 2000 units.
Hemostasis was judged to be effective in 58 (69%) patients. Two subjects were diagnosed with ischemic stroke 5 and 10 days after PCC administration. 31 In a Canadian study, 66 patients on rivaroxaban or apixaban with major bleeding were treated with four-factor PCC at a fixed dose of 2000 units. Hemostatic efficacy was assessed as good, moderate, and poor in 65%, 20%, and 15% of patients, respectively. Five (8%) patients experienced thromboembolic events at 30 days. 32 In settings where four-factor PCC is not available, some experts have advocated supplementing three-factor PCC with fresh frozen plasma to provide factor VII. APCC and recombinant factor VIIa for reversal of oral factor Xa inhibitors have been investigated in in vitro, animal, and healthy volunteer studies (reviewed in 23 ), but not in prospective studies of patients with factor Xa inhibitor-associated bleeding.
Although others have recommended weight-based dosing of fourfactor PCC (50 units/kg) for factor Xa inhibitor reversal, 20 we prefer a fixed dose of 2000 units because it has been studied in patients with factor Xa inhibitor-associated bleeding. 31, 32 Additional advantages of fixed dosing include greater simplicity for the ordering provider and pharmacy and reduced cost.
| Guidance statement 3
In patients with rivaroxaban-associated or apixaban-associated major bleeding in whom a reversal agent is warranted (see guidance statement 1), we suggest treatment with andexanet alfa dosed according to the US FDA label ( Table 2) . If andexanet alfa is not available, we suggest treatment with four-factor PCC 2000 units.
In patients with edoxaban-associated or betrixaban-associated major bleeding in whom a reversal agent is warranted (see Guidance statement 1), we suggest off-label treatment with either high dose andexanet alfa (800 mg bolus followed by a continuous infusion of 8 mg/min for up to 120 min) or four-factor PCC 2000 units.
| (4)
When should reversal agents be used before an invasive procedure?
| Evidence summary
In light of the cost and prothrombotic potential of DOAC reversal agents, their use should only be considered before an invasive procedure if (a) the bleeding risk associated with the procedure is sufficiently high that it cannot be safely performed while the patient is anticoagulated and (b) the procedure is emergent (ie, cannot be delayed).
Procedures with minimal bleeding risk (eg, minor dermatological procedures, cataract surgery, minor dental procedures) do not warrant interruption of anticoagulants and may proceed without DOAC interruption or reversal. 33, 34 In addition, emerging evidence for certain cardiac electrophysiology procedures has demonstrated equivalent or superior safety with continuation of anticoagulation. [35] [36] [37] The use of reversal agents in advance of such procedures is likely not necessary, irrespective of the urgency of the procedure.
Other procedures require temporary interruption of anticoagulation. In the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study, 10 3007 patients taking rivaroxaban, apixaban, or dabigatran for atrial fibrillation who were scheduled for an elective procedure requiring interruption of anticoagulation were managed using a standardized protocol. For patients undergoing a low bleeding risk procedure, anticoagulation was held one day before surgery. For those undergoing a high bleeding risk procedure, anticoagulation was held two days before surgery. Anticoagulation was held for longer in patients taking dabigatran with a creatinine clearance <50 mL/min (2 days before minor and 4 days before major surgery). Outcomes were favorable; the incidence of major bleeding and arterial thromboembolism at 30 days was <2% and <1%, respectively. Although laboratory measurement of DOAC levels was not used to guide management, a post hoc analysis demonstrated that plasma DOAC levels were low (<50 ng/mL) or undetectable at the time of surgery in more than 90% of patients.
38
If the patient requires an emergent procedure that cannot be safely delayed in accordance with the PAUSE protocol, 10 
| Guidance statement 4
3.5 | (5) How should reversal agents be used to manage a dabigatran-treated patient before an invasive procedure?
| Evidence summary
Idarucizumab was evaluated in 202 dabigatran-treated patients requiring an urgent invasive procedure in the REVERSE-AD study.
The median time from idarucizumab infusion to initiation of the procedure was 1.6 h. Of 197 evaluable patients, periprocedural hemostasis was judged to be normal, mildly abnormal, or moderately abnormal in 93.4%, 5.1%, and 1.5% of patients, respectively. None had severely abnormal hemostasis. 21 On the basis of these findings, the US FDA approved idarucizumab for reversal of dabigatran prior to urgent procedures. 13 As with reversal of dabigatran-associated major bleeding, the dose is 5 g (two 2.5 g vials).
There are no published data on use of APCC for reversal prior to surgery in dabigatran-treated patients. Justification for treatment in this context is extrapolated from indirect evidence from studies of bleeding patients 22 as well as in vitro, animal, and healthy volunteer studies (reviewed in 23 ) (see "(2) How should reversal agents be used to manage dabigatran-associated bleeding?" above). 3.6 | (6) How should reversal agents be used to manage a factor Xa inhibitor-treated patient before an invasive procedure?
There are no published data on use of andexanet alfa, APCC, or PCC for reversal prior to surgery in factor Xa inhibitor-treated patients.
Justification for treatment with these agents for this indication is extrapolated from indirect evidence from studies of bleeding patients 26, 31, 32 as well as in vitro, animal, and healthy volunteer studies (reviewed in 23 ) (see "(3) How should reversal agents be used to manage factor Xa inhibitor-associated bleeding?").
| Guidance statement 6
In factor Xa inhibitor-treated patients who require an urgent procedure and in whom a reversal agent is warranted (see guidance statement 4), we suggest treatment with andexanet alfa at the same dosing used for major bleeding. If andexanet alfa is not available, we suggest treatment with four-factor PCC 2000 units. Most patients with acute DOAC overdose, however, do not present with bleeding. In one study of 52 patients with acute dabigatran, rivaroxaban, or apixaban over-dosage, 7 (13%) presented with major bleeding, 2 presented with minor bleeding, and 43 were asymptomatic. 41 Management of such patients in published case reports is highly variable. Several cases of massive rivaroxaban overdose have been managed successfully without bleeding and without administration of blood products or reversal agents, attributed in part to the saturation of gastrointestinal absorption at dosages above 50 mg.
42-45
Cases involving apixaban and dabigatran have likewise been conservatively managed with success. [46] [47] [48] [49] While blood products and idarucizumab have also been administered safely in some overdose cases, their impact on clinical outcomes is unclear. 41, 42, [50] [51] [52] [53] Considering the uncertain risk of bleeding due to overdose, the relatively short half-life of the DOACs, the cost and prothrombotic potential of reversal agents, and the lack of evidence supporting their use in this context, the authors suggest that DOAC reversal agents not be routinely administered in cases of DOAC overdose without bleeding. DOAC reversal may be considered in special cases in which the patient is judged to be at high risk for catastrophic bleeding (eg, recent neurosurgery).
| Guidance statement 7
In patients with DOAC overdose without bleeding, we suggest against the routine use of reversal agents. Most trauma patients on a DOAC do not present with bleeding.
Thirty-one patients taking dabigatran, rivaroxaban, or apixaban presented to a level I trauma center after a ground level fall with head injury. None had intracranial hemorrhage. 54 In another center, of 33 dabigatran-treated patients who presented after blunt head trauma, only one was found to have intracranial hemorrhage. Among the other 32 patients, one received a reversal agent (for cervical spine fracture). The remaining 31 patients did not receive a reversal agent and had generally favorable outcomes. 55 Considering the variable and relatively low incidence of bleeding with trauma, the cost and prothrombotic potential of reversal agents, and the lack of evidence supporting their use for this indication, the authors suggest that reversal agents not be routinely administered to DOAC-treated patients presenting with trauma without bleeding.
| Guidance statement 8
In DOAC-treated patients who present with trauma without bleeding, we suggest against the routine use of reversal agents.
3.9 | (9) What strategies can be employed by health systems to promote optimal utilization of DOAC reversal agents?
| Evidence summary
There are several real and potential challenges associated with DOAC reversal strategies that may be broadly grouped into acquisition and cost, operational logistics, and appropriate utilization. Upstream recognition of and familiarity with these challenges will allow health systems and individual clinicians to develop and implement strategies for optimal use of DOAC reversal agents.
As health systems vary significantly in their available resources, structure, and function, a "one-size-fits-all" approach for optimizing DOAC reversal is not possible. However, there are core tenets related to DOAC reversal that should be applied across all hospitals, including utilization of standardized, system-level, multidisciplinary efforts that promote shared stewardship of these therapies. If resources permit, a dedicated antithrombosis stewardship team may be particularly beneficial for spearheading development, implementation, and maintenance of necessary tools and systematic processes pertaining to DOAC reversal. 56 Regardless of chosen structure or involved parties, efforts should be focused on multipronged strategies that effectively address challenges associated with DOAC reversal. given reversal agent is not sufficient to stock all hospitals, it may be prudent for hospitals within a geographic region to discuss some type of medication sharing strategy. Alternatively, it may be preferable for critical access hospitals to have the drug on hand so they can "drip and ship" the patient to a larger medical center with more resources and advanced therapies. 58 All DOAC reversal agents are associated with significant financial cost, with specific antidotes generally being more expensive than nonspecific factor concentrates (Table 3) andexanet alfa may be able to apply for reimbursement of outpatient administration using specific C codes or J codes (personal communication with Evan Howland, Portola, January 11, 2019). 63 Close collaboration between clinicians and the health system billing department will ensure optimal use of these cost mitigation strategies.
| Acquisition and cost

| Operational logistics
Given the high cost and prothrombotic potential of DOAC reversal agents, judicious use is essential. Centralized, controlled access is prudent to optimize appropriate use (eg, indication, dosing) and storage 
| Appropriate utilization
It is important for health systems to conduct regular formulary and protocol reviews to identify needed modifications based on availability and evolving evidence pertaining to DOAC reversal strategies. For example, the specific antidotes have relatively short half-lives ( 61, 66, 67 and is likely to be true of DOAC reversal strategies as well. Idarucizumab is specific for dabigatran reversal, and will have no effect on factor Xa inhibitors. Similarly, andexanet alfa will not reverse dabigatran. Utilization of the incorrect specific antidote may lead to patient harm and unnecessary drug costs. Use of standardized electronic order sets that contain evidence-based clinical decision support will facilitate efficient selection of the appropriate reversal strategy for a given clinical situation. 
| Guidance statement 9
To promote optimal use of DOAC reversal practices, we suggest that health systems develop and implement overarching strategies that promote multidisciplinary, shared stewardship of these agents. We suggest utilization of evidence-based clinical tools and processes that facilitate adherence with agreed-upon restrictions for judicious prescribing and use.
We suggest system-level approaches be streamlined to the fullest extent possible via leveraging of the electronic health record, as well as maximized efficiency of pharmacy order processing, admixture, and delivery strategies. We further suggest that health systems develop contingency plans to be prepared for acquisition challenges, as well as close collaboration with vendors and billing departments to capitalize on cost mitigation opportunities. We suggest periodic formal evaluation of DOAC reversal practices to assess for appropriateness and identify opportunities for further optimization. Lastly, we suggest that dedicated stewardship programs be established. Whenever possible, they should be used to drive development, implementation, consistent application, and evaluation of anticoagulation-related optimization strategies including, but not limited to, appropriate and judicious use of DOAC reversal agents.
| CONCLUSION
With the recent advent of potentially life-saving, but also costly and potentially prothrombotic DOAC reversal agents, it is imperative that clinicians and institutions be prepared to use these agents in a manner that is both cost-effective and optimizes patient outcomes. Prudent use of DOAC reversal agents requires consideration of indications and appropriate use; knowledge of how the agents are stored, prepared, and administered; and management strategies and stewardship at the health system level. Table 1 and Figure 1 summarize our guidance statements for DOAC reversal.
